San Francisco, CA, United States of America

Robert Lowell Simmons

USPTO Granted Patents = 9 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 5)

Average Co-Inventor Count = 9.4

ph-index = 3

Forward Citations = 32(Granted Patents)

Location History:

San Francisco, CA (US) (2014 - 2019)
Emeryville, CA (US) (2020)
San Francsico, CA (US) (2021)

Company Filing History:

Sunesis Pharmaceuticals, Inc.

patents

1 out of 850

Millennium Pharmaceuticals Limited

patents

where one patent can have more than one assignee

Years Active: 2014-2021

Loading Chart...

9 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10919887 - Salts and solid forms of a monobactam antibiotic (2021-02-16),

2. 10597396 - Beta-lactamase inhibitors (2020-03-24),

3. 10369138 - Monobactam organic compounds for the treatment of bacterial infections (2019-08-06),

4. 10065957 - Beta-lactamase inhibitors (2018-09-04),

5. 9873693 - Methods of treatment using pyridinonyl PDK1 inhibitors (2018-01-23),

6. 9174978 - Monobactam organic compounds for the treatment of bacterial infections (2015-11-03),

7. 9173883 - Ring-substituted N-pyridinyl amides as kinase inhibitors (2015-11-03),

8. 8987457 - Ring-substituted N-pyridinyl amides as kinase inhibitors (2015-03-24),

9. 8778977 - Pyridinonyl PDK1 inhibitors (2014-07-15),

Title: The Innovative Journey of Robert Lowell Simmons

Introduction

Robert Lowell Simmons, a prominent inventor based in San Francisco, CA, has made significant contributions to the field of pharmaceuticals, holding an impressive total of 9 patents. His work primarily focuses on antibiotic development, showcasing his commitment to enhancing medical treatments.

Latest Patents

Among his latest innovations are pivotal patents that include new solid forms and salts of a monobactam antibiotic. This invention specifically relates to 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid, referred to as Compound X. Furthermore, he has developed beta-lactamase inhibitors, which comprise compounds that act to inhibit beta-lactamase, with applications in treating infections caused by Gram-negative bacteria, including resistant strains.

Career Highlights

Simmons has had a notable career, holding positions at leading companies such as Novartis AG and Sunesis Pharmaceuticals, Inc. His expertise has propelled advancements in antibiotic development, positioning him as a key figure in pharmaceutical innovation.

Collaborations

Throughout his career, Simmons has collaborated with various talented individuals, including his coworkers Anthony Casarez and Folkert Reck. These collaborations have been instrumental in driving his inventions forward, fostering an environment of innovation and discovery.

Conclusion

Robert Lowell Simmons continues to be a crucial contributor to the pharmaceutical industry through his innovative patents and collaborative efforts. His work not only advances antibiotic treatment options but also exemplifies the power of innovation in addressing critical healthcare challenges.

This text is generated by artificial intelligence and may not be accurate.